Boothbay Fund Management’s Connect Biopharma Holdings CNTB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.32M Sell
973,732
-260,850
-21% -$632K 0.03% 662
2026
Q1
$3.23M Hold
1,234,582
0.04% 447
2025
Q4
$3.48M Buy
+1,234,582
New +$2.63M 0.05% 414
2023
Q3
Sell
-26,867
Closed -$30.4K 1784
2023
Q2
$30.4K Hold
26,867
﹤0.01% 1701
2023
Q1
$26.9K Hold
26,867
﹤0.01% 2051
2022
Q4
$23.3K Hold
26,867
﹤0.01% 1917
2022
Q3
$35K Sell
26,867
-50,984
-65% -$61.3K ﹤0.01% 2137
2022
Q2
$68K Hold
77,851
﹤0.01% 2046
2022
Q1
$235K Buy
77,851
+48,167
+162% +$203K 0.01% 1790
2021
Q4
$153K Buy
+29,684
New +$330K ﹤0.01% 1584

Other funds holding CNTB

Boothbay Fund Management's CNTB Position: Q2 2026 in Review

Boothbay Fund Management reduced its Connect Biopharma Holdings (CNTB) stake by 21% in Q2 2026, selling an estimated $632K and leaving 973,732 shares worth $2.32M. The position accounts for 0.03% of the portfolio, ranked #662.

Boothbay Fund Management first reported a position in CNTB in Q4 2021 and has held it in 10 quarters since. The position peaked at $3.48M in Q4 2025. 56 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

  • Boothbay Fund Management held 973,732 shares of Connect Biopharma Holdings worth $2.32M as of Q2 2026.
  • Boothbay Fund Management sold 260,850 Connect Biopharma Holdings shares in Q2 2026, an estimated $632K.
  • Connect Biopharma Holdings made up 0.03% of Boothbay Fund Management's portfolio in Q2 2026, its #662 holding.
  • Boothbay Fund Management first reported a position in Connect Biopharma Holdings in Q4 2021 and has held it in 10 quarters since.
  • Boothbay Fund Management's Connect Biopharma Holdings position peaked at $3.48M in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.